193 related articles for article (PubMed ID: 29867453)
1. Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells.
Li Q; Yue Y; Chen L; Xu C; Wang Y; Du L; Xue X; Liu Q; Wang Y; Fan F
Front Pharmacol; 2018; 9():334. PubMed ID: 29867453
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
3. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
4. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells.
Lee MS; Lim SH; Yu AR; Hwang CY; Kang I; Yeo EJ
Biology (Basel); 2021 Feb; 10(2):. PubMed ID: 33671902
[TBL] [Abstract][Full Text] [Related]
7. Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy.
Hsu CM; Yen CH; Wang SC; Liu YC; Huang CT; Wang MH; Chuang TM; Ke YL; Yeh TJ; Gau YC; Du JS; Wang HC; Cho SF; Tsai Y; Hsiao CE; Hsiao SY; Hsiao HH
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884943
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium.
Hjazi A; Maroto CG; Rodriguez-Gutierrez ME; Appiah M; Ignat A; Mobayen G; Page T; McKinnon TAJ
J Thromb Haemost; 2024 Apr; ():. PubMed ID: 38608731
[TBL] [Abstract][Full Text] [Related]
9. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Hanke NT; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Nabissi M; Morelli MB; Offidani M; Amantini C; Gentili S; Soriani A; Cardinali C; Leoni P; Santoni G
Oncotarget; 2016 Nov; 7(47):77543-77557. PubMed ID: 27769052
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway.
Dabour MS; Abdelgawad IY; Grant MKO; El-Sawaf ES; Zordoky BN
Biomed Pharmacother; 2023 Aug; 164():114907. PubMed ID: 37247463
[TBL] [Abstract][Full Text] [Related]
13. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
14. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells.
Lee SI; Jeong YJ; Yu AR; Kwak HJ; Cha JY; Kang I; Yeo EJ
Sci Rep; 2019 Mar; 9(1):5039. PubMed ID: 30911132
[TBL] [Abstract][Full Text] [Related]
18. Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Imam F; Al-Harbi NO; Al-Harbi MM; Ansari MA; Almutairi MM; Alshammari M; Almukhlafi TS; Ansari MN; Aljerian K; Ahmad SF
Toxicol Mech Methods; 2016 Nov; 26(9):700-708. PubMed ID: 27785949
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi NO
Toxicol Mech Methods; 2016; 26(3):189-95. PubMed ID: 26899300
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib.
Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
